2029, FDA, Prospecting and Sales

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

FDA

Prospecting

Sales

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3

pharmaphorum

OCTOBER 26, 2022

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis and other interstitial lung diseases (ILDs). First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5

Recruitment

Recruitment Prospecting Marketing Patients

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

MAY 17, 2023

The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. Data from the analyses will be used for a potential end-of-Phase II study meeting with the FDA. billion in 2029.

Food and Drug Administration

Food and Drug Administration FDA Pharmaceutical Prospecting

Pharma Rep Focus

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3

Intercept receives orphan drug designation for liver disease combo therapy

Stay Connected